Results 51 to 60 of about 65,035 (206)
BMC Gastroenterology, 2003 Background Evidence based medicine depends on unbiased selection of completed randomized controlled trials. For completeness it is important to publish all trials.
Delwaide Jean +7 more
doaj +1 more source
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. [PDF]
PLoS ONE, 2016 In this pilot study (RibaC), 58 hepatitis C virus (HCV) genotype 1 infected treatment-naïve patients were randomized to (i) 2 weeks ribavirin double dosing concomitant with pegylated interferon-α (pegIFN-α), (ii) 4 weeks ribavirin mono-therapy prior to ...
Jesper Waldenström +13 more
doaj +1 more source
Analysis of Hepatitis C Viral Dynamics Using Latin Hypercube Sampling
, 2011 We consider a mathematical model comprising of four coupled ordinary differential equations (ODEs) for studying the hepatitis C (HCV) viral dynamics. The model embodies the efficacies of a combination therapy of interferon and ribavirin.
Dahari +17 more
core +1 more source
Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients [PDF]
, 2018 BACKGROUND: Microbial translocation from the gut lumen has been involved in the pathogenesis of liver damage in hepatitis C virus (HCV) infection. AIM: To investigate the impact of direct-acting antiviral treatment on microbial translocation and T ...
Baroncelli, Silvia +10 more
core +1 more source
Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients
Hepatology Research, EarlyView.ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki +10 more
wiley +1 more source
Emerging Infectious Diseases, 2018 We performed a systematic review and meta-analysis on the effectiveness of ribavirin use for the prevention of infection and death of healthcare workers exposed to patients with Crimean-Congo hemorrhagic fever virus (CCHFV) infection. Splashes with blood
Önder Ergönül +7 more
doaj +1 more source
Influence of Ribavirin on Mumps Virus Population Diversity
Viruses, 2021 Frequent mumps outbreaks in vaccinated populations and the occurrence of neurological complications (e.g., aseptic meningitis or encephalitis) in patients with mumps indicate the need for the development of more efficient vaccines as well as specific ...
Mirna Jurković +5 more
doaj +1 more source
Hepatology Research, EarlyView.The post‐to pretreatment serum CXCL10 ratio was independently associated with short‐term liver function outcome following HCV eradication in cirrhotic patients. ABSTRACT Aim The prognostic value of serum C‐X‐C motif chemokine ligand 10 (CXCL10) levels for liver function was investigated in hepatitis C virus (HCV)–infected patients with compensated or ...
Takanori Suzuki +20 more
wiley +1 more source
Effect of Ribavirin on Hepatitis A Virus Replication In Vitro
Canadian Journal of Infectious Diseases, 1992 The effect of ribavirin on fetal Rhesus monkey kidney cells (FRhK-4) acutely or chronically infected with hepatitis A virus was studied. The effect of ribavirin on hepatitis A virus yield as detected by radioimmunoassay in acutely infected FRhK-4 cells ...
Rabindra K Chaudhary, Anton P Andonov
doaj +1 more source
Journal of the Formosan Medical Association, 2020 Background/Purpose: The major dose-limiting toxicity of ribavirin is hemolytic anemia. We investigated the incidence, risk factors and impact on virological response of anemia in chronic hepatitis C genotype 2 patients receiving sofosbuvir plus ribavirin
Chi-Ching Chen +10 more
doaj +1 more source